Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing
Metrics: PDF 1254 views | HTML 1390 views | ?
Song Wu1,4,*, Zhao Yang2,3,*, Rui Ye5,*, Dan An5,*, Chong Li2,*, Yitian Wang4,6,*, Yongqiang Wang7, Yi Huang4, Huan Liu5, Feida Li5, Luyun He2, Da Sun5, Yuan Yu5, Qiaoling Li5, Peide Huang5, Meng Zhang6, Xin Zhao5, Tengteng Bi5, Xuehan Zhuang5, Liyan Zhang5, Jingxiao Lu4, Xiaojuan Sun4, Fangjian Zhou7, Chunxiao Liu8, Guosheng Yang9, Yong Hou5, Zusen Fan2 and Zhiming Cai4,6
1 The Affiliated Luohu Hospital of Shenzhen University, Shenzhen Luohu Hospital Group, Shenzhen, China
2 CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
3 CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
4 Department of Urological Surgery, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
5 BGI-Shenzhen, Shenzhen, China
6 Anhui Medical University, Hefei, China
7 Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China
8 Department of Urology, Zhujiang Hospital of Southern Medical University, Guangzhou, China
9 Guangdong Second People’s Hospital, Guangzhou, China
* These authors have contributed equally to this work
Zhiming Cai, email:
Zusen Fan, email:
Keywords: bladder cancer, tumor recurrence, MLL, drug-resistance, whole-exome sequencing
Received: May 27, 2015 Accepted: October 14, 2015 Published: November 25, 2015
Bladder cancer (BC) is distinguished by high rate of recurrence after surgery, but the underlying mechanisms remain poorly understood. Here we performed the whole-exome sequencing of 37 BC individuals including 20 primary and 17 recurrent samples in which the primary and recurrent samples were not from the same patient. We uncovered that MLL, EP400, PRDM2, ANK3 and CHD5 exclusively altered in recurrent BCs. Specifically, the recurrent BCs and bladder cancer cells with MLL mutation displayed increased histone H3 tri-methyl K4 (H3K4me3) modification in tissue and cell levels and showed enhanced expression of GATA4 and ETS1 downstream. What’s more, MLL mutated bladder cancer cells obtained with CRISPR/Cas9 showed increased ability of drug-resistance to epirubicin (a chemotherapy drug for bladder cancer) than wild type cells. Additionally, the BC patients with high expression of GATA4 and ETS1 significantly displayed shorter lifespan than patients with low expression. Our study provided an overview of the genetic basis of recrudescent bladder cancer and discovered that genetic alterations of MLL were involved in BC relapse. The increased modification of H3K4me3 and expression of GATA4 and ETS1 would be the promising targets for the diagnosis and therapy of relapsed bladder cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.